Invasive bladder cancer: ignoring the data.

about

Invasive bladder cancer: ignoring the data.

Item

http://www.wikidata.org/entity/Q42575248

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Invasive bladder cancer: ignoring the data.

@en

Invasive bladder cancer: ignoring the data.

@nl

type

Item

label

Invasive bladder cancer: ignoring the data.

@en

Invasive bladder cancer: ignoring the data.

@nl

prefLabel

Invasive bladder cancer: ignoring the data.

@en

Invasive bladder cancer: ignoring the data.

@nl

P1476

Invasive bladder cancer: ignoring the data.

@en

P2093

Derek Raghavan

http://www.w3.org/2001/XMLSchema#string

P2860

Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.

Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up.

International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.

Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis.

Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status.

Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer.

Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer.

Initial combination chemotherapy with cisplatin, methotrexate and vinblastine in locally advanced transitional cell carcinoma--response rate and pitfalls. MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party).

P304

895-896

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1634/THEONCOLOGIST.2013-0281

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256201854

http://www.w3.org/2001/XMLSchema#string

P698

23986339

http://www.w3.org/2001/XMLSchema#string

P932

3755924

http://www.w3.org/2001/XMLSchema#string